While an excess of glucocorticoids is associated with hippocampal pathology in mood disorders, lithium exerts robust neuroprotective and neurotrophic effects. Here, 21 stably remitted bipolar I patients who had been on chronic lithium maintenance therapy, on average, for more than a decade, and 19 carefully matched healthy controls were studied using 3 T 1 Hmagnetic resonance spectroscopy of left and right hippocampus. Salivary cortisol samples were obtained to assess activity of the hypothalamus-pituitary-adrenal system. Absolute concentrations of N-acetylaspartate (NAA), choline-containing compounds and total creatine were similar in euthymic bipolar patients and healthy controls. Hippocampal glutamate concentrations were significantly increased as an effect of patient status (patients > controls) and laterality (left hippocampus > right hippocampus). Hippocampal glutamate content (Glu) was strongly correlated with NAA. Across groups and within the patient group, diurnal saliva cortisol levels showed a significant inverse relationship with both Glu and NAA. Taken together, these results add to the concept of bipolar disorder as an illness involving disturbed hippocampal structural plasticity under the opposing influences of lithium and glucocorticoids.
Introduction
Bipolar disorder is a common, recurrent and severe mental illness characterized by mood swings of elation and depression. 1, 2 A growing body of evidence suggests that impaired cellular plasticity and resilience may contribute toward central nervous system structural alterations associated with affective illness. [3] [4] [5] The hippocampal formation is a particularly plastic and vulnerable brain region. Direct clinical evidence for hippocampal pathology in bipolar illness stems from post-mortem histological analysis, [6] [7] [8] [9] volumetric magnetic resonance imaging 10 and [(18)F]fluorodeoxyglucose-positron emission tomography. 11 Recently, magnetic resonance spectroscopy (MRS) has also provided evidence for hippocampal neurometabolite alterations in bipolar disorder. [12] [13] [14] After 50 years of clinical use, lithium salts have remained the most effective and widely used longterm preventive treatment for bipolar disorder to date. 15, 16 Lithium robustly upregulates the neuroprotective protein BCL2 on the outer mitochondrial membrane and confers neuroprotection in a model of transient focal cerebral ischemia in rats. 17, 18 Subchronic treatment with lithium also increases nerve growth factor content in hippocampus and induces adult dentate granule cell neogenesis. 19, 20 Short-term lithium administration at therapeutic doses to initially depressed bipolar patients elicits distinct brain structural changes including a rise in N-acetyl-aspartate concentration (NAA) and growth of neuropil manifesting as increases in gray matter volume. 21, 22 Notably, short-term lithium administration has recently been reported to increase hippocampal volume bilaterally in bipolar patients. 23 The glutamatergic system has been implicated in the pathophysiology and treatment of mood disorders. 24, 25 However, to date, absolute brain glutamate concentrations in bipolar patients have not been determined quantitatively in vivo. 26 A recent study of post-mortem human frontal cortex from the Stanley Foundation Brain Collection reported increased glutamate levels in bipolar disorder. 27 However, this finding is hard to interpret as it may reflect either an effect of psychopharmacotherapy (two-thirds of patients were receiving mood stabilizers at the time of death) or of an active disease process (suicide was the cause of death in three-fifths of patients). 28 There is ample evidence implicating abnormalities of the hypothalamus-pituitary-adrenal (HPA) system in bipolar disorder. 29, 30 Glucocorticoids and stress enhance glutamatergic transmission in the hippocampus. 31, 32 Glucocorticoids, through increased glutamatergic signaling, elicit structural remodeling in the hippocampus such as dendritic atrophy, 33, 34 an effect that can be prevented by lithium treatment. 35 Notably, chronic treatment with lithium stabilizes glutamate uptake in presynaptic nerve endings over a narrow range 36 and produces a robust neuroprotective effect against excitotoxicity. 37 High glucocorticoid levels and stress have also been documented to impair hippocampal neurogenesis whereas blockade of glutamatergic neurotransmission with N-methyl-D-aspartic acid receptor antagonist MK-801 increases precursor proliferation. 38, 39 In the present study, neurometabolite concentrations in hippocampus of bipolar patients in stable remission on long-term lithium maintenance and of matched controls were investigated in vivo with proton MRS ( 1 H-MRS). Together with the concentrations of NAA, choline-containing compounds and total creatine (tCr), glutamate levels were determined with a previously developed spectroscopy method using point-resolved spectroscopy (PRESS)-based single voxel MRS at 3 T. 40, 41 We sought to specifically address the interrelationships between hippocampal glutamate concentrations, other metabolites and activity of the HPA system.
Materials and methods

Participants
Patients were recruited from the department's specialized bipolar disorder outpatient clinic. Study patients had to meet the following inclusion criteria: a Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV)-TR diagnosis of bipolar I disorder; continuous maintenance treatment with lithium, documented by measurement of serum lithium levels; length of time on lithium prophylaxis of at least 3 years. Plasma lithium levels were measured every 4-8 weeks (target levels: 0.5-0.9 mmol l
À1
) with dosage regularly adjusted accordingly.
Healthy controls matched for age, gender and educational level were recruited by advertisement, notices posted at the medical center and by word of mouth. Control group participants had no family history of mood or psychotic disorder, and no personal history of Axis I or II disorders as determined by clinical interview and by the Structured Clinical Interview for DSM-IV. 42 Control group participants had no history of lithium or antidepressant intake.
Patients and controls were at least 18 years of age. Additional exclusion criteria for both patients and controls included a history of head injury, evidence or history of transient ischemic attack or stroke, as well as any current clinically relevant medical condition.
The protocol had been approved by the local ethics committee and written informed consent was obtained from each participant according to the Declaration of Helsinki.
Hormonal measurements
Saliva cortisol measurements were essentially performed as described previously. 3, 43 Briefly, saliva for the estimation of free cortisol concentrations was collected from all participants (Salivette, Sarstedt, Germany) over 3 days prior to magnetic resonance imaging (MRI) examination. Saliva samples were obtained at the following time points: immediately after awakening (approximately 0700; TP1), 30 min after awakening (approximately 0730; TP2), 1100 (TP3), 1500 (TP4) and 2100 (TP5). Saliva samples of day 1 were considered practice samples and discarded. For each time point, mean cortisol values of days 2 and 3 were calculated for further statistical analysis.
Clear saliva was used for duplicate analyses of cortisol using a time-resolved immunoassay with fluorescence detection. The lower limit of detection was 0.43 nmol l À1 with interassay and intraassay coefficients of variation of less than 10% across the expected range of cortisol levels (3-25 nmol l
À1
). Saliva cortisol measurements have been shown to reflect activity of the HPA system in depressed patients. 43, 44 MR spectroscopy Data acquisition. Magnetic resonance measurements were carried out on a 3 T scanner (MEDSPEC 30/100, Bruker Biospin, Ettlingen, Germany) using a circularly polarized head coil. After automated global shim of the linear, xz, z 2 and x 2 -y 2 field components, T 1 -weighted images were acquired using modified driven equilibrium Fourier transform (MDEFT, T E = 3.8 ms, T R = 20.53 ms; 128 contiguous slices, 1.5 mm thick; 1 mm inplane (x-y) resolution). Magnetic resonance spectra were acquired from two voxels of 2 Â 3 Â 2 cm 3 volume each, including the left and right hippocampi (Figure 1a) .
After manual shimming to a waterline width (fullwidth at half maximum) of 7-9 Hz the radiofrequency power needed for a 901 excitation pulse was determined. Subsequently, calibration of water suppression (three Gaussian pulses of 25.6 ms duration) was carried out, followed by acquisition of spectra with the PRESS sequence using a Shinnar-LeRouxoptimized 901 pulse and Mao refocusing pulses. Eight subspectra of 16 phase-cycled scans each were recorded with T R = 3 s, yielding 128 averages. To ensure maximum selectivity for the glutamate C4 resonance while maintaining a fair signal-to-noise (SNR) ratio for the singlet resonances, an echo time of 80 ms was chosen as result of extensive preliminary studies. 40 Data processing. The eight individual metabolite subspectra were corrected for eddy currents using waterunsuppressed spectra. They were then frequency-aligned to compensate frequency drifts during spectrum acquisition 45 and added together to give 128 averages.
Spectral quantification was carried out using a program package based on a time-domain frequency domainfitting procedure. 40, 46 This method involves automatic correction for frequency shifts caused by involuntary subject motion and system instabilities, inclusion of phantom basis spectra and prior knowledge into the fit, and background estimation. In the present spectra, the resonances of total choline (tCho, total creatine (tCr), NAA, and glutamate and glutamine resonances were fitted by inclusion of phantom spectra (0.1 M metabolite at pH 7.2 and 37 1C in spherical bottles) for the latter three, and imposing constant frequency differences for glutamate, glutamine and NAA, and equal line widths as prior knowledge. 40 At the chosen echo time of 80 ms, the baseline was not entirely flat. To account for baseline features, the fitting procedure routinely includes estimation of the baseline nonparametrically by regularization. 47 Extensive tests yielded mean uncertainties (corresponding to Cramér-Rao lower bounds with added uncertainties from baseline modeling) for the fitting of NAA of 2.7%, tCho of 4.0%, tCr of 3.0% and glutamate of 13.1%. Uncertainties for glutamine were above 50% and therefore precluded further consideration of this parameter. Metabolite amplitudes returned by the fitting procedure were corrected for different coil loading by the phantoms and the individual subject's head (principle of reciprocity) and for transverse relaxation effects using T 2 values measured in the hippocampus voxel. 40 Regarding longitudinal relaxation, the deviation caused by the T 1 effect at T R = 3 s and an assumed T 1 of glutamate at 3 T of about 1.2 s 48 was largely compensated by the deviation estimated for the aqueous, buffered glutamate phantom where T R was set at 5 s and T 1 was determined to be 1.47 s. Thus, glutamate might, at worst, be systematically underestimated by about 5% owing to unaccounted T 1 effects, which would lead to uniform scaling of the calculated concentrations. However, because we did not determine the true T 1 values of glutamate in the voxels of interest, the correction remains speculative and was therefore neglected.
It should be noted that g-aminobutyric acid (GABA), a major candidate interfering molecule in the quantification of the glutamate C4 resonance (and a neurotransmitter whose concentration might change as well), was not included in the spectrum analysis. However, extensive tests on both metabolite phantoms and in vivo brain spectra 40 indicated our fitting procedure to be largely insensitive to GABA contribution, mainly because of the fair separation of the two resonance signals at the chosen echo time of 80 ms. Since our analysis method is not capable of quantifying the low level of GABA in brain reliably, this metabolite was omitted from the fit. The relative insensitivity of our method against contributions by aspartate, the resonances of which are close to the region of the glutamate C4 resonance of interest, has also been shown previously. 41 To correct the Typical point-resolved spectroscopy (PRESS) spectrum (T R = 3 s and T E = 80 ms) acquired from a voxel containing the hippocampus. The C4 proton multiplet resonance of glutamate used for quantification is highlighted. TCr, total creatine; tCho, total choline; NAA, N-acetylaspartate.
Elevated glutamate in euthymic bipolar patients M Colla et al metabolite concentrations for the fraction of cerebrospinal fluid (CSF) in the voxels studied, the latter was calculated by segmenting the T 1 -weighted images into gray matter, white matter and CSF using spm99. 49 Classification of pixels was based on which spm99 tissue classification had the greatest probability.
Statistical analyses
Neurometabolite concentrations are reported as the mean of left and right hippocampal measurements ( Table 2 ). All numerical analyses were performed with the versatile statistics package JMP 6.0.2 (SAS Comp.) on a Macintosh system (10.4.7). Comparisons between patients and healthy control subjects were carried out by means of analysis of variance (ANOVA). The Pearson's correlation coefficient was used to detect correlations among and between MRI measures and clinical data. Average cortisol values of days 2 and 3 of all five time points were standardized by Z-transformation for each participant. These normalized cortisol values were then averaged across all five time points (average diurnal cortisol). All tests were performed at a level of significance equal to 0.05. All values are given as mean ± s.e.m.
Results
Study population
A total of 21 outpatients with bipolar disorder in stable remission on long-term lithium maintenance and 19 healthy controls carefully matched for age and education were enrolled into the study. Patients' plasma lithium concentrations measured within a week of MRI were 0.7±0.03 mmol l
À1
. Sociodemographic characteristics of the study sample are given in Table 1 . Patients and controls were similar in age, gender, height and years of education. Body weight tended to be higher in patients on lithium maintenance relative to healthy controls (F 1,38 = 3.24, P = 0.08, 1-b = 0.4). In addition to lithium, one patient received sertraline as adjunctive psychopharmacotherapy. On average, patients had been in remission for 12 years (minimum 3 years, maximum 23 years) and had received lithium prophylaxis for 15 years (minimum 3 years, maximum 30 years).
Neurometabolite levels in controls and in remitted patients on chronic lithium maintenance therapy Positioning of hippocampal voxels and a representative PRESS spectrum are shown in Figure 1 . Absolute neurometabolite concentrations (mean and individual left and right values) are summarized in Table 2 . Mean hippocampal neurometabolite concentrations for NAA, tCr and tCho did not differ significantly between patient and control groups. Across groups, glutamate concentrations were higher in the left hippocampus than in the right hippocampus (F 1,78 = 7.2, P = 0.009). Two-way ANOVA with factors laterality (left versus right cerebral hemisphere) and status (patients versus controls) yielded a significant effect of side (F 1,78 = 7.2, P = 0.009, post hoc left versus right hippocampus: P = 0.007) and status (F 1,78 = 4.2, P = 0.04, Fisher's post hoc test healthy participant versus patient: P = 0.04) on hippocampal glutamate content (Glu). The correlation between left and right hippocampal glutamate levels was R = 0.31, F 1,38 = 4.1, P = 0.05.
Across groups, we did not detect a significant relationship between body mass index (kg m
À2
) and hippocampal glutamate levels (not shown). Age was not significantly correlated with hippocampal glutamate concentrations (across groups: R = 0.04, F 1,38 = 0.07, P = 0.80).
Significant positive relationship between hippocampal NAA and hippocampal glutamate levels Across groups, we observed a significant strong positive correlation between hippocampal glutamate and hippocampal NAA levels ( Figure 2) . A within-group Mean±s.e.m. Inverse correlation between diurnal saliva cortisol levels and hippocampal NAA and glutamate concentrations Descriptively, at all time points investigated, saliva cortisol concentrations were lower in the patient group than in the control group (Figure 3a) . Importantly, the early morning cortisol peak was significantly reduced in the patient group (F 1,38 = 4.1, P = 0.05). Across groups, hippocampal NAA levels were inversely correlated with average diurnal cortisol (entire study population: Figure 3b ; patients: R = À0.51, F 1,19 = 6.7, P = 0.02; controls: R = À0.18, F 1,17 = 0.6, P = 0.47). Likewise, hippocampal Glu was inversely correlated with average diurnal cortisol across groups (entire study population: Figure 3c ; patients: R = À0.71, F 1,19 = 19.1, P = 0.0003; controls: R = À0.21, F 1,17 = 0.8, P = 0.39). Correlations between saliva cortisol levels at each time point investigated and hippocampal NAA and glutamate concentrations are given in Table 3 .
Discussion
This study has the following major findings: relative to healthy controls, bipolar I patients in stable remission on long-term lithium prophylaxis showed increased absolute hippocampal glutamate levels especially in the left hippocampus. In both patients and controls, hippocampal glutamate and hippocampal NAA concentrations were strongly correlated. Across groups and within the patient group, diurnal cortisol levels showed a significant inverse relationship with both hippocampal Glu and NAA concentrations.
To our knowledge, this is the first published report of absolute glutamate levels in hippocampus in bipolar disorder in vivo. Due to the complex spin system of glutamate (leading to J-coupling), conventional MRS at lower field strengths produces a poor resolution spectrum composed of glutamate, glutamine and GABA, together designated Glx. At the field strength of 3 T employed here, a fair separation of the glutamate C4 resonance from interfering signals can be achieved, allowing for quantification of the neurotransmitter with high reliability. A crucial parameter for quantification is the SNR ratio, which is proportional to voxel size. The voxel size of 12 ml chosen here offered the best compromise between adequate SNR and undesired partial volume contribution of neighboring medial temporal lobe structures. However, the volume of the adult hippocampus proper excluding entorhinal, parahippocampal and perirhinal cortices is at around 2 ml (for example, Colla et al.
3
). We observed increased hippocampal glutamate levels in stably remitted patients on chronic lithium maintenance relative to healthy controls. Hippocampal glutamate concentrations reported here are in general agreement with values previously determined at autopsy. 50, 51 Our results are also in general agreement with a recent report of increased levels of glutamate in post-mortem frontal cortex samples from patients with bipolar disorder 27 and an 1 H-MRS investigation at 1.5 T that previously reported increased anterior cingulate cortical glutamate in bipolar depression. 52 However, information on antidepressant intake in the latter study is lacking while a subset of patients are reported to have received lithium.
While investigations of other brain regions have yielded less conclusive results, 26 so far, examinations of the hippocampal formation in bipolar disorder by means of spectroscopy have consistently demonstrated a regional reduction of NAA signal. [12] [13] [14] 53 Patients included in these studies were either firstepisode manic, 12 or a group of patients with mood states ranging from hypomanic to depressed 13 or patients who had been euthymic for at least 2 months before study entry.
14 Reduced hippocampal NAA/Cr ratios have also been reported transnosographically for patients with a first episode of an affective psychosis. 53 By contrast, patients enrolled in this study had been in stable remission on average for more than a decade (minimum 3 years) and had received long-term documented lithium prophylaxis. The finding of normal NAA levels in our unique patient sample is conceptually consistent with the notion that lithium's beneficial effects may be due to its neurotrophic and neuroprotective properties 54, 55 and fits well with an earlier report that described a lithium-induced increase in brain NAA. 21 To our knowledge, this is also the first study to describe a strong positive correlation between glutamate and NAA concentrations in the human hippocampus in vivo. A similar correlation between glutamate and NAA has previously been reported in perchloric acid extracts of biopsy specimens of epileptogenic human hippocampus. 56 Importantly, this robust association between NAA and glutamate levels held even in the presence of a high degree of neuronal loss and over a wide range of NAA levels. 56 In line with these observations, studies using 13 C MRS have demonstrated that the rate of glutamate labeling from 13 C-glucose infusion (a measure of the activity of the Krebs cycle in neurons) and NAA synthesis appear to be tightly coupled. 57 A recent hypothesis posits that NAA serves as a reservoir for glutamate and, in an energetically favorable set of reactions, is dynamically converted into glutamate when necessary.
58 Table 3 Pearson's correlations between saliva cortisol measurements and hippocampal metabolite concentrations Elevated Glx signal has been reported in global gray matter of symptomatic (predominantly depressed), medication-free bipolar patients, 59 in frontal lobes and basal ganglia of children aged 6 to 12 years suffering from bipolar disorder 60 and in left dorsolateral prefrontal cortex in acute mania. 61 However, at the low field strengths used, the Glx peak is difficult to separate into glutamate, glutamine and GABA, and therefore difficult to interpret. Elevated glutamate concentrations would be hard to reconcile with earlier findings of reduced NAA levels in bipolar disorder 13, 14, 62, 63 if the NAA/glutamate ratio remains constant during active disease.
Clearly, brain Glu cannot simply be equated with glutamatergic neurotransmission. Rather, it represents a composite multicell multicompartment signal. Glutamate is a versatile amino acid involved in protein biosynthesis, synaptic transmission and the precursor for the inhibitory GABA. It is also a key intermediate in cellular metabolism. In the brain, glutamate is distributed into distinct pools. Estimates of the relative sizes of the glutamate pools have yielded neuronal/glial ratios of glutamate of around 9:1. [64] [65] [66] [67] In neurons, the size of the glutamate metabolic pool located in the cytosol far exceeds the size of the vesicular glutamate neurotransmitter pool. Extracellular and vesicular glutamate represent only a small fraction of total brain glutamate. 68, 69 Conceivably, lithium at levels generally associated with maintenance therapy may exert an inducing effect on Glu through stimulation of neuronal and glial metabolism, neurogenesis in the hippocampus as well as gliogenesis in the hippocampus and possibly elsewhere in the brain. Along these lines, we have recently reported that glutamate levels in the dorsolateral prefrontal cortex in major depression increase with clinical improvement. 70 Interestingly, in this study we also observed a significant positive correlation between serum lithium levels and hippocampal glutamate concentrations for lithium levels > 0.5 and < 1.0 mmol l À1 (not shown). Obviously, different glutamate pools will be affected differentially by lithium treatment also depending on dosage administered. This would be in line both with the observation that chronic lithium treatment stabilizes glutamate uptake by presynaptic nerve endings 36 and that short-term high-dose lithium treatment (2 mmol kg À1 b.i.d. over 2 weeks) decreases whole-brain glutamate concentrations in rats. 71 Conversely, another recent study in rats found that lower doses of lithium led to increases in cortical glutamate concentration. 72 Notably, it is also an established clinical fact that lithium levels required for an acute antimanic response (that is, > 0.9 mmol l À1 ) exceed those required for relapse prevention.
To date, effects of laterality on hippocampal neurochemistry of patients suffering from bipolar disorder have not been observed. [12] [13] [14] 53 Similarly, we also did not detect an effect of side on absolute hippocampal NAA concentrations in our patient sample. Given the importance ascribed to the right hemisphere in emotions and mood, it is of special interest to note that relative to controls right hippocampal glutamate levels in patients were not reduced. With the paucity of spectroscopic studies of hippocampus in bipolar disorder, the significance of the novel finding of increased left hippocampal glutamate concentrations in patients is hard to judge. One likely hypothesis would be that glutamate levels are increased beyond normalization by chronic lithium maintenance.
Disturbances in glucocorticoid receptor signaling and regulation of HPA system activity in bipolar disorder have been described in numerous studies. 29, 30, [73] [74] [75] Glucocorticoids and stress impair adult hippocampal neurogenesis and have been shown to induce morphological changes at the cellular level such as atrophy of dendritic processes particularly in the hippocampus. 38, [76] [77] [78] This prompted us to investigate the relationship between Glu and NAA as markers of cerebral metabolism and cortisol. So far, studies on the effect of circulating glucocorticoids on brain Glu are lacking.
The negative correlations between diurnal cortisol and both hippocampal glutamate and NAA concentrations observed in this study fit well within the concept of disturbed neuroplasticity in mood disorders. Consistent with our results, reduced hippocampal NAA ratios have been described in prescription corticosteroid-treated patients. 79 Importantly, the negative correlation between average diurnal cortisol and glutamate was stronger in bipolar patients as compared to healthy controls despite the fact that average diurnal cortisol was actually dampened in patients on chronic lithium prophylaxis (Table 3) . It is an intriguing speculation that patients suffering from bipolar disorder are biologically more sensitive to the adverse effects of stress and glucocorticoids. In this context it is also worth mentioning that glucocorticoid receptor transgenic mice represent a promising novel molecular model of mood disorders. 80, 81 On a technical note, saliva concentrations for the five time points reported here are averages of measurements of saliva samples taken on 2 consecutive days after a practice day. Also, morning saliva measurements were carefully related to awakening and rising. The importance of this particular point is illustrated by the steep cortisol increase between TP1 and TP2. Furthermore, all patients investigated here belonged to a homogenous asymptomatic group.
In conclusion, numerous studies have demonstrated lithium's neuroprotective, neurotrophic and antiapoptotic effects [17] [18] [19] [20] [21] [22] [23] 35, 37 and highlighted the importance of glucocorticoids for hippocampal structure and function. [33] [34] [35] 38, 77, 78, 80 The results reported here add to the concept of bipolar disorder as an illness involving disturbed hippocampal structural plasticity under the opposing influences of lithium and glucocorticoids.
